Here's Why Alleged 'Junk Patents' Could Make Drugs Like Ozempic Pricier
The “bogus” patent listings keep brand name drug prices “artificially high,” regulators said.
Source: forbes.com
Impax Labs News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Impax Labs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Impax Labs Today - Breaking & Trending Today
FTC Spoke, Kaleo and Impax Listened: Orange Book Patent Delistings Begin | Axinn, Veltrop & Harkrider LLP
As discussed last month, the FTC sent letters to 10 pharmaceutical companies, asserting that their listing of over 100 patents in FDA’s Orange Book for a variety of products was...
Source: jdsupra.com
10 Years after Actavis, the Cases that Follow Tell a Story | Haug Partners LLP
I. Introduction - No pharmaceutical antitrust decision has had more impact than the Supreme Court’s 2013 decision in Federal Trade Commission v. Actavis, a decision which...
Source: jdsupra.com
D.C. Circuit Dismisses FTC Antitrust Suit: Exclusive Pharma Patent Licenses Remain Permissible Under The Patent Act - Antitrust, EU Competition
On Friday, August 25, 2023, the U.S. Court of Appeals For The District Of Columbia Circuit affirmed dismissal of an antitrust action brought by the Federal Trade Commission...
Source: mondaq.com
Status Of Reverse Payment Cases Against Pharmaceutical Companies - Patent
Reverse payment cases arise in the context of settlement agreements between brand-name pharmaceutical companies and generic drug manufacturers to resolve patent litigation under the Hatch-Waxman Act...
Source: mondaq.com